Clinical Trials Logo

Stage II Uterine Corpus Cancer clinical trials

View clinical trials related to Stage II Uterine Corpus Cancer.

Filter by:

NCT ID: NCT03422198 Recruiting - Clinical trials for Endometrial Serous Adenocarcinoma

Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer

SAVE
Start date: January 30, 2018
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies short course vaginal cuff brachytherapy to see how well it works compared with standard of care vaginal cuff brachytherapy in treating participants with stage I-II endometrial cancer. Short course vaginal cuff brachytherapy, also known as internal radiation therapy, uses (over a shorter period) radioactive material placed directly into or near a tumor in the upper portion of the vagina to kill tumor cells. After completion of cohort 1 (108 participants), the protocol was expended to add a second cohort of 80 additional participants, and re-opened study recruitment.

NCT ID: NCT03198286 Completed - Clinical trials for Stage IIIA Breast Cancer

Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors

Start date: August 1, 2015
Phase: N/A
Study type: Interventional

This pilot clinical trial studies how well the Carevive Survivor Care Planning System works in improving quality of life in breast cancer survivors. A personalized survivor care plan includes a summary of a patient's cancer treatment and a customized survivor care plan and may provide beneficial information and resources.

NCT ID: NCT02575872 Completed - Clinical trials for Stage II Uterine Corpus Cancer

Physical Activity Behavioral Intervention in Obese Endometrial Cancer Survivors

Start date: October 2013
Phase: N/A
Study type: Interventional

This randomized clinical trial studies a physical activity behavioral intervention in obese endometrial cancer survivors. Learning about physical activity behavior while participating in a fitness class may help increase physical activity and improve the quality of life of obese endometrial cancer survivors.

NCT ID: NCT02342730 Completed - Clinical trials for Stage II Uterine Corpus Cancer

Weight Loss Referral for Healthier Survivorship in Obese Stage I-II Endometrial Cancer Survivors or Atypical Hyperplasia

Start date: December 17, 2014
Phase: N/A
Study type: Interventional

This pilot clinical trial studies whether obese stage I-II endometrial cancer survivors or patients with atypical hyperplasia (abnormal cells in the lining of the uterus) would go see a weight loss specialist if it was recommended by their cancer doctor. Excess body weight or obesity is one of the most common contributors to (causes of) endometrial cancer. Over two-thirds of women who have survived endometrial cancer are obese. Complications of obesity, such as heart disease are often more dangerous than the cancer itself. A weight loss of even 5-10% of excess body weight is associated with improved health. Often, meeting with a doctor or person who is an expert in weight loss (bariatric specialist) is the best way to lose weight and keep it off. Endometrial cancer survivors or patients with atypical hyperplasia who go see a weight loss specialist recommended by their doctor may be able to achieve a healthier body weight.

NCT ID: NCT01522820 Completed - Glioblastoma Clinical Trials

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Start date: March 2012
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best schedule of vaccine therapy with or without sirolimus in treating patients with cancer-testis antigen (NY-ESO-1) expressing solid tumors. Biological therapies, such as sirolimus, may stimulate the immune system in different ways and stop tumor cells from growing. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells that express NY-ESO-1. Infusing the vaccine directly into a lymph node may cause a stronger immune response and kill more tumor cells. It is not yet known whether vaccine therapy works better when given with or without sirolimus in treating solid tumors.

NCT ID: NCT01344837 Not yet recruiting - Clinical trials for Endometrial Serous Adenocarcinoma

Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer

Start date: January 2100
Phase: N/A
Study type: Observational

This research study is studying biomarkers in blood and tissue samples from patients with uterine cancer. Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes the occur in DNA and identify biomarkers related to cancer.

NCT ID: NCT01208467 Completed - Clinical trials for Endometrial Adenocarcinoma

Prognostic Biomarkers in Patients With Endometrial Cancer

Start date: September 2010
Phase: N/A
Study type: Observational

This research study is studying prognostic biomarkers in tissue samples from patients with endometrial cancer. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

NCT ID: NCT01199250 Not yet recruiting - Lynch Syndrome Clinical Trials

Biomarkers in Samples From Patients With Endometrial Cancer

Start date: January 2100
Phase: N/A
Study type: Observational

This research study is studying biomarkers in samples from patients with endometrial cancer. Studying samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

NCT ID: NCT01198171 Not yet recruiting - Clinical trials for Stage II Uterine Corpus Cancer

Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial Cancer

Start date: January 2100
Phase: N/A
Study type: Observational

This research study is studying racial and genetic biomarkers of response in tissue samples from patients with endometrial cancer. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. DNA analysis of tumor tissue may also help doctors predict how well patients will respond to treatment.

NCT ID: NCT01098630 Completed - Clinical trials for Recurrent Cervical Carcinoma

Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer

Start date: July 2010
Phase:
Study type: Observational

This clinical trial is studying patient, physician, and nurse factors associated with entry onto clinical trials and finishing treatment in patients with primary or recurrent uterine, endometrial, or cervical cancer. Determining how patients make decisions about participating in a clinical trial may help doctors plan clinical trials in which more patients are willing to participate and are satisfied with their decision to participate.